Boston Scientific's Patent Verdict Reversed by Federal Court
The US Court of Appeals for the Federal Circuit has overturned a $42 million patent verdict against Boston Scientific (BSX). The decision reverses an earlier jury ruling in favor of the University of Texas, which had claimed that Boston Scientific infringed on its drug-eluting stent technology. This reversal is significant as it removes a major financial liability from Boston Scientific and could impact future litigation involving medical device patents. Drug-eluting stents are widely used to treat coronary artery disease by preventing re-narrowing of blood vessels after angioplasty procedures. The case had drawn attention due to the high stakes involved in patent disputes within the medical technology sector, where intellectual property rights can heavily influence market competition and innovation.
Tickers: $BSX
Topics: court decision medical devices patents